PTC Stock Recent News

DENVER--(BUSINESS WIRE)--CoreSite, a leading hybrid IT solutions provider and subsidiary of American Tower Corporation (NYSE: AMT) (“American Tower”), will participate in the upcoming Pacific Telecommunications Conference 2025 January 19-22 at the Hilton Hawaiian Village Waikiki Beach Resort in Honolulu, Hawaii. The annual PTC event provides a strategic springboard to focus on planning, networking and discovering what lies ahead for the digital infrastructure, information and communication tech.

BOSTON , Jan. 15, 2025 /PRNewswire/ -- PTC (Nasdaq: PTC) will release its fiscal 2025 first quarter results on Wednesday, February 5 th after the stock market closes. Senior management will host a live webcast and conference call to review the results on Wednesday, February 5 th at 5 pm Eastern Time.

WARREN, N.J. , Jan. 13, 2025 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on Jan. 3, 2025, the company approved 1,200 restricted stock units ("RSUs"), each representing the right to receive one share of its common stock upon vesting, to two new employees.

– Unaudited 2024 total revenue of approximately $814 million, exceeding guidance – – Four approval applications submitted to FDA in 2024 – – Global launch preparations underway for sepiapterin for PKU, a $1 billion market opportunity; CHMP opinion expected Q2 2025, U.S. approval decision in July 2025 –  – License and collaboration agreement with Novartis for PTC518 program closed – – PIVOT-HD data readout for PTC518 expected Q2 2025 – WARREN, N.J. , Jan. 13, 2025 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today provided an update on the Company's progress and its outlook for 2025.

PTC reported better-than-expected FQ4 2024 results, but faces challenges in top line revenue growth due to macro headwinds and go-to-market changes. The global PLM market is projected to grow at a 9.2% CAGR through 2030, driven by cloud-based systems and smart product demand. PTC's financials show improved operating income and gross margins, but international revenue growth is lagging, particularly in Europe.

BOSTON , Oct. 16, 2024 /PRNewswire/ -- PTC (Nasdaq: PTC) will release its fiscal 2024 fourth quarter and full year results on Wednesday, November 6 th after the stock market closes. Senior management will host a live webcast and conference call to review the results on Wednesday, November 6 th at 5pm Eastern Time.

- Statistically significant results on primary endpoint of long-term study analyses - - Following FDA pre-NDA feedback, submission on track for December 2024 - WARREN, N.J. , Oct. 8, 2024 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) provided today several positive updates on the vatiquinone Friedreich ataxia (FA) program.

WARREN, N.J. , Oct. 1, 2024 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today the FDA has accepted for filing the New Drug Application (NDA) of sepiapterin for the treatment of pediatric and adult patients living with phenylketonuria (PKU).

PTC Inc. PTC has inked a Strategic Collaboration Agreement with Amazon Web Services (“AWS”) to boost the growth of its Onshape solution. This collaboration aims to enhance Onshape's capabilities, promote customer adoption and advance AI initiatives, all intended to help designers and engineers create high-quality products more swiftly and efficiently.

Collaboration to Drive PTC's Onshape Initiatives Including Discovery Program, Onshape AI Advisor, and CAD and PDM Conversion Tools BOSTON , Sept. 25, 2024 /PRNewswire/ -- PTC (NASDAQ: PTC) today announced entry into a Strategic Collaboration Agreement (SCA) with Amazon Web Services (AWS) to accelerate the growth of its Onshape® cloud-native computer-aided design (CAD) and product data management (PDM) solution.